Press Releases

See our recent news and announcements below. If you have any questions or for media inquiries, please contact for assistance or see specified media contact details within each release.

Bridgewater, NJ, Tuesday, April 18, 2023

Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing transformative medicines for patients with cancer, and its partner GeneQuantum Healthcare (Suzhou) Co. Ltd, a privately-held biotechnology company based in China, announced data at the American Association for Cancer Research (AACR) Annual Meeting 2023 highlighting the preclinical efficacy and safety profile of GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2), across several in vitro and in vivo models.

[read more…]


Pyramid Biosciences Expands Oncology Pipeline with In-Licensing of GQ1010, a Potentially Best-in-Class TROP2 Targeted Antibody Drug Conjugate (ADC) from GeneQuantum Healthcare

Pyramid Biosciences to Present at the B. Riley Securities Third Annual Oncology Conference

Pyramid Biosciences To Present at the 2022 Jefferies London Healthcare Conference

Pyramid Biosciences Names Biren Amin as Chief Financial and Strategy Officer

Pyramid Biosciences Names Nushmia Khokhar, MD, as Chief Medical Officer

Pyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDA

Pyramid Biosciences Announces TIME Trial™ Program Collaboration with Tempus for Patients with NTRK Fusion Solid Tumors

Pyramid Biosciences and Caris Life Sciences Announce MI Trials Collaboration for Clinical Trial Matching in Support of Study for Patients with NTRK Fusion Solid Tumors

Pyramid Biosciences Appoints Brian Lestini, MD, PhD as Chief Executive Officer

Pyramid Biosciences Expands Precision Oncology Pipeline

Pyramid Biosciences Announces Initial Closing of Series B Financing for Clinical Program Acceleration

Pyramid Biosciences Announces First Patients Dosed in Phase 1 Clinical Program for Dermatology

Pyramid Biosciences Announces Leadership Team Expansion

Pyramid Biosciences Secures $28 Million in Funding to Accelerate Clinical Programs

Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases